← Back to Search

Monoclonal Antibodies

Ilumya for Psoriasis

Phase 4
Recruiting
Research Sponsored by Psoriasis Treatment Center of Central New Jersey
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 16 weeks
Awards & highlights
Pivotal Trial
All Individual Drugs Already Approved
No Placebo-Only Group
Drug Has Already Been Approved

Summary

This trial will test the effectiveness of Ilumya, a new psoriasis treatment, either alone or in combination with Halog ointment.

Eligible Conditions
  • Psoriasis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 16 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Body surface area

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.

Trial Design

1Treatment groups
Experimental Treatment
Group I: IlumyaExperimental Treatment1 Intervention
Ilumya 100mg subcutaneous at weeks 0, 4 and 16.

Find a Location

Who is running the clinical trial?

Psoriasis Treatment Center of Central New JerseyLead Sponsor
14 Previous Clinical Trials
417 Total Patients Enrolled
13 Trials studying Psoriasis
377 Patients Enrolled for Psoriasis
Sun Pharmaceutical Industries LimitedIndustry Sponsor
69 Previous Clinical Trials
13,770 Total Patients Enrolled
14 Trials studying Psoriasis
2,869 Patients Enrolled for Psoriasis
~4 spots leftby Nov 2025